TY - JOUR
T1 - Influenza and pneumococcal vaccine prescription for adults during COVID-19 first wave in three regions of Argentina
AU - Matta, María Gabriela
AU - Pulido, Laura
AU - Herrera-Paz, Juan José
AU - Picco, José M.
AU - Wolff, Sebastian
AU - Tse, Gary
AU - Garcia-Zamora, Sebastian
N1 - Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/2/24
Y1 - 2023/2/24
N2 - Immunizations for influenza and pneumococcus are effective interventions in reducing morbidity and mortality. The objective of this study was to describe the vaccination rates in volunteers from three regions of Argentina during the COVID-19 pandemic. In 2020, 3853 adults were surveyed, 61.6 % were females, 45 % were aged between 40 and 60 and 18.6 % were > 60 years old. The commonest comorbidities were hypertension (12.9 %), dyslipidemia (8.5 %), and smokers or former smokers (9.2 %). The global influenza vaccination rate was 37.7 %, pneumococcal vaccination 24.7 %, and both 17.8 %. Multivariable regression showed that the vaccination rate increased with age and the presence of comorbidities. However, in the subgroup with indications for both vaccines, 71.7 % had the influenza vaccine, 59 % had the pneumococcal vaccine, and 28.3 % received neither. Our study suggests that influenza and pneumococcal vaccine percentages in high-risk patients in Argentina remain sub-optimal. Immunizations with proven reductions in morbimortality could have also been relegated during the COVID pandemic.
AB - Immunizations for influenza and pneumococcus are effective interventions in reducing morbidity and mortality. The objective of this study was to describe the vaccination rates in volunteers from three regions of Argentina during the COVID-19 pandemic. In 2020, 3853 adults were surveyed, 61.6 % were females, 45 % were aged between 40 and 60 and 18.6 % were > 60 years old. The commonest comorbidities were hypertension (12.9 %), dyslipidemia (8.5 %), and smokers or former smokers (9.2 %). The global influenza vaccination rate was 37.7 %, pneumococcal vaccination 24.7 %, and both 17.8 %. Multivariable regression showed that the vaccination rate increased with age and the presence of comorbidities. However, in the subgroup with indications for both vaccines, 71.7 % had the influenza vaccine, 59 % had the pneumococcal vaccine, and 28.3 % received neither. Our study suggests that influenza and pneumococcal vaccine percentages in high-risk patients in Argentina remain sub-optimal. Immunizations with proven reductions in morbimortality could have also been relegated during the COVID pandemic.
KW - Immunization
KW - Influenza vaccine
KW - Pneumococcal vaccine
UR - http://www.scopus.com/inward/record.url?scp=85147101718&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2023.01.056
DO - 10.1016/j.vaccine.2023.01.056
M3 - Article
C2 - 36725429
AN - SCOPUS:85147101718
SN - 0264-410X
VL - 41
SP - 1541
EP - 1544
JO - Vaccine
JF - Vaccine
IS - 9
ER -